| ORIGINAL ARTICLE |
|
| Year : 2000 | Volume
: 1
| Issue : 7 | Page : 248-250 |
|
|
Amplatzer atrial septal defect closure device used in adult patients
Bernard E F Hockings, James L Wilkinson, Cheryl Blanton
Cardiology Department, Sir Charles Gairdner Hospital, Mount Hospital & University of Western , Perth and Royal Children's Hospital, Melbourne, Australia
Correspondence Address:
Bernard E F Hockings
Mount Cardiology, Suite 3, 140 Mounts Bay Road, Perth, Western Australia 6000
Australia
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Percutaneous Amplatzer device closure of atrial septal defects has been gaining popularity in recent years, mainly in children. Its use in adults began in October 1996. In May 1997, the first Australian adult was treated with the device. As of July 1, 1999, 160 devices have been implanted in Australia, one-third of these in adults. Data was collected on 63 adult patients aged 16 – 78 years. Of the 63 patients, 52 underwent successful implantation. 5 patients were brought back for a second procedure because the first device implanted was smaller in size than the size of the defect. The device is now available in sizes ranging from 10 to 38mm. 23 patients have had the device implanted in Perth and 3 patients underwent a second procedure when a larger device became available. Not all patients were symptomatic before the procedure, but of those who were, 18 of 34 were symptomatically improved. 21 of 36 patients with right-sided dilatation showed reduction in size of the right atrium and right ventricle at 2 – 19 months of follow-up. Potential problems include difficulty in sizing the device correctly, embolization (1 patient), and transient ST segment elevation (2 patients). Our experience shows that the Amplatzer ASD closure device can be used successfully in adult patients.
|
|
|
|
| [PDF]* |
|
 |
|
